Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2003-09-08
2009-11-03
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S408000, C530S351000
Reexamination Certificate
active
07611700
ABSTRACT:
Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.
REFERENCES:
patent: 3171820 (1965-03-01), Volz et al.
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4462985 (1984-07-01), Cummins, Jr.
patent: 4497795 (1985-02-01), Cummins
patent: 4503035 (1985-03-01), Pestka et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4678751 (1987-07-01), Goeddel
patent: 4797368 (1989-01-01), Carter et al.
patent: 4820514 (1989-04-01), Cummins
patent: 4820515 (1989-04-01), Cummins
patent: 4820638 (1989-04-01), Swetly et al.
patent: 5017371 (1991-05-01), Cummins
patent: 5019382 (1991-05-01), Cummins, Jr.
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5198345 (1993-03-01), Gwynne et al.
patent: 5215741 (1993-06-01), Young et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5441734 (1995-08-01), Reichert et al.
patent: 5460956 (1995-10-01), Reichert et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5602232 (1997-02-01), Reichert et al.
patent: 5676942 (1997-10-01), Testa et al.
patent: 5710027 (1998-01-01), Hauptmann et al.
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5753500 (1998-05-01), Shenk et al.
patent: 5763239 (1998-06-01), Short et al.
patent: 5770434 (1998-06-01), Huse
patent: 5779434 (1998-07-01), De Long
patent: 5798208 (1998-08-01), Crea
patent: 5798390 (1998-08-01), Weber et al.
patent: 5817307 (1998-10-01), Cummins
patent: 5824300 (1998-10-01), Cummins
patent: 5830456 (1998-11-01), Cummins
patent: 5837500 (1998-11-01), Ladner et al.
patent: 5846526 (1998-12-01), Cummins
patent: 5862514 (1999-01-01), Huse et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 5871974 (1999-02-01), Huse
patent: 5882640 (1999-03-01), Cummins
patent: 5910304 (1999-06-01), Cummins
patent: 5925565 (1999-07-01), Berlioz et al.
patent: 5997858 (1999-12-01), Tovey et al.
patent: 6001574 (1999-12-01), Short et al.
patent: 6013478 (2000-01-01), Wells et al.
patent: 6036949 (2000-03-01), Richards et al.
patent: 6057103 (2000-05-01), Short
patent: 6096548 (2000-08-01), Stemmer
patent: 6117679 (2000-09-01), Stemmer
patent: 6127175 (2000-10-01), Vigne et al.
patent: 6132970 (2000-10-01), Stemmer
patent: 6153420 (2000-11-01), Sheppard
patent: 6156509 (2000-12-01), Schellenberger
patent: 6165458 (2000-12-01), Foldvari et al.
patent: 6165793 (2000-12-01), Stemmer
patent: 6171820 (2001-01-01), Short
patent: 6174673 (2001-01-01), Short et al.
patent: 6180406 (2001-01-01), Stemmer
patent: 6204022 (2001-03-01), Johnson et al.
patent: 6207145 (2001-03-01), Tovey
patent: 6238884 (2001-05-01), Short et al.
patent: 6258530 (2001-07-01), Huse
patent: 6299870 (2001-10-01), Pestka
patent: 6299872 (2001-10-01), Albrecht et al.
patent: 6300474 (2001-10-01), Pestka
patent: 6319691 (2001-11-01), Pang
patent: 6346243 (2002-02-01), Brod
patent: 6361769 (2002-03-01), Tovey
patent: 6372218 (2002-04-01), Cummins
patent: 6387365 (2002-05-01), Albrecht et al.
patent: 6455253 (2002-09-01), Patten et al.
patent: 6461605 (2002-10-01), Cutler et al.
patent: 6479258 (2002-11-01), Short
patent: 6482613 (2002-11-01), Goeddel et al.
patent: 6485480 (2002-11-01), Brewitt
patent: 6506377 (2003-01-01), Cummins et al.
patent: 6608183 (2003-08-01), Cox, III
patent: 6610830 (2003-08-01), Goeddel et al.
patent: 6815184 (2004-11-01), Stomp et al.
patent: 6846844 (2005-01-01), Tang
patent: 6884411 (2005-04-01), Tarro et al.
patent: 6897297 (2005-05-01), Pepinsky et al.
patent: 6946125 (2005-09-01), Rahal
patent: 2001/0043915 (2001-11-01), Frey
patent: 2002/0081574 (2002-06-01), Collett et al.
patent: 2003/0129203 (2003-07-01), Vega et al.
patent: 2003/0129584 (2003-07-01), Vega
patent: 2003/0134351 (2003-07-01), Vega et al.
patent: 2003/0175694 (2003-09-01), Vega
patent: 2003/0224404 (2003-12-01), Vega et al.
patent: 2004/0002474 (2004-01-01), Heinrichs et al.
patent: 2004/0081635 (2004-04-01), Cummins et al.
patent: 2004/0082026 (2004-04-01), DeFrees et al.
patent: 2004/0219131 (2004-11-01), Patten et al.
patent: 2004/0230040 (2004-11-01), Cox
patent: 2005/0019871 (2005-01-01), Lee et al.
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 2005/0058621 (2005-03-01), Cox
patent: 2005/0202438 (2005-09-01), Gantier et al.
patent: 2006/0020116 (2006-01-01), Gantier et al.
patent: 2006/0020396 (2006-01-01), Gantier et al.
patent: 2006/0094655 (2006-05-01), Guyon et al.
patent: 2007/0172459 (2007-07-01), Gantier et al.
patent: 0 146 903 (1985-07-01), None
patent: 0 240 224 (1987-10-01), None
patent: 0 240 224 (1987-10-01), None
patent: 0 051 873 (1989-09-01), None
patent: 0 625 991 (1999-04-01), None
patent: 1022335 (2000-07-01), None
patent: 2802645 (2001-06-01), None
patent: 2808804 (2001-11-01), None
patent: WO 91/02000 (1991-02-01), None
patent: 95/23813 (1995-09-01), None
patent: 9738723 (1997-10-01), None
patent: 98/13487 (1998-04-01), None
patent: 9832880 (1998-07-01), None
patent: 99/07833 (1999-02-01), None
patent: 99/11764 (1999-03-01), None
patent: 99/64582 (1999-12-01), None
patent: 01/25253 (2001-04-01), None
patent: 01/25438 (2001-04-01), None
patent: 01/32844 (2001-05-01), None
patent: 0132711 (2001-05-01), None
patent: WO/01/36001 (2001-05-01), None
patent: 0144809 (2001-06-01), None
patent: 01/61344 (2001-08-01), None
patent: 0186291 (2001-11-01), None
patent: 0186291 (2001-11-01), None
patent: 02/16606 (2002-02-01), None
patent: 02/085941 (2002-10-01), None
patent: 03018820 (2003-03-01), None
patent: 03023032 (2003-03-01), None
patent: 2004/019856 (2004-03-01), None
patent: 2004/022593 (2004-03-01), None
patent: 2004/022747 (2004-03-01), None
patent: 2004/031352 (2004-04-01), None
patent: 2004/074486 (2004-09-01), None
patent: 2005/003157 (2005-01-01), None
patent: 2006/024547 (2006-03-01), None
Blank et al., Identification of a linear epitope of Interferonalpha-2b recognized by neutralizing monoclonal antibodies. Eur. J. Biochem 265, Nov. 19, 1999.
Walter MR, Three-Dimensional Models of Interferon-alpha Subtypes IFN-con I, IFN-a8, and IFN-a1 Derived From the Crystal Structure of IFN- alpha 2b. (Semin. Oncol. 24, S9-52 to S9-62, 1997.
Black et al., A Pre-aspartate-specific Protease from Human Leukocytes That Cleaves Pro-interleukin- 1beta. J. Biol. Chem. 264, 5323-5326, 1989.
Bernkop-Schnurch, A. The use of inhibitory agents to overcome the enzymatic barrier to per orally administered therapeutic peptides and proteins. J. Controlled release, 52, 1-16, 1998.
Yan et al., Neoglycoproteins: In Vitro Introduction of Glycosyl Units at Glutamines in beta-Casein Using Transglutaminase, Biochem. 23, 3759-3765, 1984.
Callard and Gearing,The Cytokine Facts Book, Academic Press, San Diego, pp. 157-158, (1994).
Fumero, S., “Belerofon: a Long-lasting and Orally Available Interferon Alpha” (Meeting Abstract)Third Annual Optimizing Protein and Antibody Therapeutics, Pioneering New Frontiers(Jan. 10, 2007) http://www.chi-peptalk.com/06—PTT.asp.
Martin,, P., “Beyond the Next Generation of Therapeutic proteins,” Oct. 2006, http://www.biotech-online.com/artimg/a20062123243425.PDF (accessed on Jan. 11, 2007) (3 pages).
Martin, P., “Next Generation Products and Prospects for the Oral Delivery of Proteins” (Meeting Abstract)Fourth Annual Protein Process Development(Jan. 11, 2007). http://www.chi-peptalk.com/06—Ppd.asp.
Martin, P., “The Market for Therapeutic Proteins: New Business Opportunities” (Meeting Abstract)Second Annual Advancing Protein Therapeutics, Engineering the Next Generation of Proteins for Therapeutics(Jan. 13, 2006). http://www.chi-peptalk.com/pttn2006.asp.
Media Release: “In Vivo Studies Provide Hope for Orally Available Protein Therapeutics” Paris, France and Boston, Massachusetts (USA) Apr. 26, 2006 http://www.prnewswire.co.uk/cgi
ews/release?id=169343 (accessed on Jan. 8, 2007)
Drittanti Lila
Gantier Rene
Guyon Thierry
Vega Manuel
Hanall Pharmaceuticals, Co., Ltd.
K&L Gates LLP
Seidman Stephanie
Spector Lorraine
Stoica Elly-Gerald
LandOfFree
Protease resistant modified interferon alpha polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease resistant modified interferon alpha polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease resistant modified interferon alpha polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4137071